Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous rocuronium after anesthesia induction
ACTRN12614001215617Phase 4Withdrawn
- Sponsor
- Fremantle Hospital
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rocuronium (2 arms), sponsored by Fremantle Hospital. Primary endpoint: Duration of muscle relaxation until train-of-four ratio recovers to 90%. Planned start Feb 2015; status: withdrawn.
02
Drugs
rocuronium
Beyond the preview
Go deeper on ACTRN12614001215617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001215617.